Scarica l'app Stockscreener
1.165
2.92%
-0.035
Dopo l'orario di chiusura:
1.11
-0.055
-4.72%
Precedente Chiudi:
$1.20
Aprire:
$1.19
Volume 24 ore:
97,095
Relative Volume:
0.51
Capitalizzazione di mercato:
$18.54M
Reddito:
$345.00K
Utile/perdita netta:
$-11.25M
Rapporto P/E:
-1.6142
EPS:
-0.7217
Flusso di cassa netto:
$-16.70M
1 W Prestazione:
-11.07%
1M Prestazione:
-21.81%
6M Prestazione:
-0.43%
1 anno Prestazione:
+7.87%
Intervallo 1D:
$1.1101
$1.21
Intervallo di 1 settimana:
$1.035
$1.31
Portata 52W:
$0.7687
$2.35
Allarity Therapeutics Inc Stock (ALLR) Company Profile
Nome
Allarity Therapeutics Inc
Settore
Industria
Telefono
401-426-4664
Indirizzo
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.165 | 19.09M | 345.00K | -11.25M | -16.70M | -0.7217 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 126.01B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 70.03B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 56.56B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 40.63B | 742.00K | -1.37B | -1.07B | -7.0731 |
Allarity Therapeutics Inc Stock (ALLR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-28 | Iniziato | Ascendiant Capital Markets | Buy |
Allarity Therapeutics Inc Borsa (ALLR) Ultime notizie
Allarity Therapeutics Obtains CLIA Certification For In-House DRP Testing And Advances Stenoparib Toward FDA Registration - marketscreener.com
Allarity Therapeutics obtains CLIA lab certification - Investing.com
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration - Investing News Network
Allarity Therapeutics obtains CLIA lab certification By Investing.com - Investing.com Nigeria
Allarity’s Denmark lab gets CLIA status for U.S. cancer-trial testing - Stock Titan
Is Allarity Therapeutics, Inc. (ALLR) Stock Outpacing Its Medical Peers This Year? - NewsBreak: Local News & Alerts
Enterprise value to EBITDA forward of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
Tranche Update on Allarity Therapeutics, Inc.'s Equity Buyback Plan announced on March 3, 2025. - marketscreener.com
Allarity Wins Key U.S. Patent for Stenoparib Diagnostic - TipRanks
Allarity Therapeutics (NASDAQ: ALLR) wins key DRP patent and secures shareholder backing - Stock Titan
Enterprise value to revenue forward of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
Allarity receives U.S. patent for stenoparib diagnostic test - Investing.com
Allarity receives U.S. patent for stenoparib diagnostic test By Investing.com - Investing.com Nigeria
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic - Yahoo Finance
Price to earnings forward of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
Price to book forward of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
Allarity wins U.S. patent protection for stenoparib test into 2042 - Stock Titan
Allarity Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALLR) - TradingView
ALLR Forecast — Price Target — Prediction for 2027 - TradingView
Is Allarity Therapeutics, Inc. (ALLR) outperforming other medical stocks this year? - MSN
Allarity Therapeutics Inc (ALLR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Allarity Therapeutics Showcases Phase 2 Stenoparib Trial Progress in Advanced Ovarian Cancer at ESMO 2026 - Minichart
Form 8K Allarity Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
Allarity Therapeutics (NASDAQ: ALLR) showcases Phase 2 stenoparib ovarian cancer trial - Stock Titan
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026 - Investing News Network
Allarity to present trial poster at cancer congress - Investing.com
Allarity to present trial poster at cancer congress By Investing.com - Investing.com Canada
Allarity Therapeutics to Present Trial-in-Progress Poster - GlobeNewswire
Allarity Therapeutics Inc (ALLR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Allarity Therapeutics Inc (ALLR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Allarity Therapeutics Inc (ALLR) Institutional Confidence - TradingKey
Allarity Therapeutics Inc (ALLR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Allarity Therapeutics Inc (ALLR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Allarity Therapeutics Inc (ALLR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Allarity Therapeutics Inc (ALLR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Allarity Therapeutics Inc (ALLR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
ALLR Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineNet Profit Margin - newsline.com
ALLR Maintained by Ascendiant Capital -- Price Target Raised to $10.25 - GuruFocus
ALLR Q1 2026 Earnings: EPS Surprises to the Upside as Clinical Advances ContinueROA Comparison - dars.gov.et
Allarity Therapeutics (ALLR) Slides 5.3% as Stock Tests Critical Support LevelGap Fill Strategy - newsline.com
Are medical stocks lagging Allarity Therapeutics, Inc. (ALLR) this year? - MSN
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year? - Yahoo Finance
Amended and Restated Management Services Agreement Between Allarity Therapeutics, Inc. and Ljungaskog Consulting AB Effective June 1, 2026 - Minichart
Allarity Therapeutics Updates CEO Management and Compensation Agreement - TipRanks
Allarity (NASDAQ: ALLR) updates CEO pay and severance terms - Stock Titan
Number of shareholders of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
ALLR Q1 2026 Earnings: Narrower Loss Surprises as Pre-Revenue Biotech Advances PipelineGuidance Downgrade Alert - The Legal Advocate
ALLRAllarity Therapeutics Inc Options - Finviz
Allarity Therapeutics Inc Azioni (ALLR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):